Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Novartis Plans Winter Park, Florida, Radioligand Manufacturing Operations

01/20/2026
Science-based pharmaceutical company Novartis plans to establish operations in Winter Park, Florida. The project is expected to create 50 jobs.

The investment will include the construction of a new 35,000-square-foot radioligand therapy manufacturing facility located at 3825 Forsyth Road. Operations are scheduled to begin in 2029.

“Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients,” said Vas Narasimhan, CEO of Novartis. “Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing US manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them.”

The project was made possible through the combined efforts of the Orlando Economic Partnership, Florida Department of Commerce, Orange County, Duke Energy, and local partners.

“Thanks to deliberate, focused, intensified investments and world class health innovation partnerships, we have led Florida to become a national and world-recognized leader for breakthroughs in cancer treatment, neurological innovations, and more,”noted Florida Secretary of Commerce J. Alex Kelly. “Novartis’ investment in manufacturing cancer medicines here in Florida—where we’re already #2 nationally in both manufacturing for medicine and medical device technology—is an incredible opportunity to welcome world class innovators to our incredibly collaborative and impactful life sciences community.”

Novartis, the sole company with two FDA-approved RLT treatments, develops medicnes in areas like oncology, cardiovascular, immunology, and neuroscience. Radioligand therapy is a precision oncology treatment that pairs a tumor-targeting molecule with a therapeutic radioisotope, delivering radiation directly to cancer cells while minimizing harm to healthy tissue.

“Novartis’ decision to expand in Orlando underscores our region’s strength and value as a hub for advanced manufacturing and life sciences innovation,” added Tim Giuliani, President and CEO of the Orlando Economic Partnership.

“Thanks to a strong collaborative relationship with the Orlando Economic Partnership, Central Florida will soon welcome Novartis, an innovative pharmaceutical manufacturer, bringing 50 new jobs to the region,” said Melissa Seixas, President, Duke Energy Florida.

Exclusive Research